Monthly
US$200
Billed every month
Sign in to subscribeLoxoprofen Sodium Tablets
As of 13 November 2026, for Loxoprofen Sodium Tablets, 3 applications are listed as under review at China's CDE; 2 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 6 holders.
Companies, stages and changes, with each record available on this page.
No changes recorded by this site in the last 90 days
Complete CDE snapshot: 2026/11/13 06:42
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Catalogue holders6View records ↓
Under-review filings3View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers10View records ↓
API companies with A status21View records ↓
Chemical-drug catalogue
Loaded records: 6 holders; 4 in the quality-and-efficacy consistency-evaluation category, and 1 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| Fujian Dong Rui Pharmaceutical Co., Ltd. romanized | Fujian Dong Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20041143 | 2024/02/02 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | 2022/05/26 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Hunan Jiudian Pharmaceutical Co., Ltd | Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | 2020/10/27 | See source | Generic approved under the new chemical-drug registration classification | CDE |
| Wei Cai (Liaoning) Pharmaceutical Co., Ltd. romanized | Wei Cai (Liaoning) Pharmaceutical Co., Ltd. romanized | 国药准字H20041923 | 2020/08/10 | 60mg | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Name not romanized | Di Sha Pharma Group Co., Ltd. romanized | 国药准字H20050437 | 2020/01/15 | See source | Drug that passed quality-and-efficacy consistency evaluation | CDE |
| Name not romanized | Di Yi San Gong Pharmaceutical (Shanghai) Co., Ltd. romanized | 国药准字H20030769 | 2003/08/05 | 60mg | Other drug | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 10 distinct approval numbers and 10 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Di Yi San Gong Pharmaceutical (Shanghai) Co., Ltd. romanized | 国药准字H20030769 | 60mg | Category B | XM01AEL283A001010100745 | NHSA |
| Shanghai Xu Dong Hai Pu Pharma Co., Ltd. romanized | 国药准字H20030614 | See source | Category B | XM01AEL283A001010100808 | NHSA |
| Tianjin Xin Feng Pharmaceutical Co., Ltd. romanized | 国药准字H20030617 | 60mg | Category B | XM01AEL283A001010100949 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010101016 | NHSA |
| Wei Cai (Liaoning) Pharmaceutical Co., Ltd. romanized | 国药准字H20041923 | 60mg | Category B | XM01AEL283A001010101337 | NHSA |
| Jilin Ying Lian Biopharmaceutical Co., Ltd. romanized | 国药准字H20050114 | 60mg | Category B | XM01AEL283A001010103336 | NHSA |
| Di Sha Pharma Group Co., Ltd. romanized | 国药准字H20050437 | See source | Category B | XM01AEL283A001010103944 | NHSA |
| Ningbo Li Hua Pharmaceutical Co., Ltd. romanized | 国药准字H20123120 | See source | Category B | XM01AEL283A001010104557 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010104942 | NHSA |
| Shanghai Xu Dong Hai Pu Pharma Co., Ltd. romanized | 国药准字H20030614 | See source | Category B | XM01AEL283A001010200808 | NHSA |
| Tianjin Xin Feng Pharmaceutical Co., Ltd. romanized | 国药准字H20030617 | 60mg | Category B | XM01AEL283A001010200949 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010201016 | NHSA |
| Wei Cai (Liaoning) Pharmaceutical Co., Ltd. romanized | 国药准字H20041923 | 60mg | Category B | XM01AEL283A001010201337 | NHSA |
| Jilin Ying Lian Biopharmaceutical Co., Ltd. romanized | 国药准字H20050114 | 60mg | Category B | XM01AEL283A001010203336 | NHSA |
| Di Sha Pharma Group Co., Ltd. romanized | 国药准字H20050437 | See source | Category B | XM01AEL283A001010203944 | NHSA |
| Ningbo Li Hua Pharmaceutical Co., Ltd. romanized | 国药准字H20123120 | See source | Category B | XM01AEL283A001010204557 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010204942 | NHSA |
| Tianjin Xin Feng Pharmaceutical Co., Ltd. romanized | 国药准字H20030617 | 60mg | Category B | XM01AEL283A001010300949 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010301016 | NHSA |
| Wei Cai (Liaoning) Pharmaceutical Co., Ltd. romanized | 国药准字H20041923 | 60mg | Category B | XM01AEL283A001010301337 | NHSA |
| Di Sha Pharma Group Co., Ltd. romanized | 国药准字H20050437 | See source | Category B | XM01AEL283A001010303944 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010304942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010401016 | NHSA |
| Di Sha Pharma Group Co., Ltd. romanized | 国药准字H20050437 | See source | Category B | XM01AEL283A001010403944 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010404942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010501016 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010504942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010601016 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010604942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010701016 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010704942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010801016 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010804942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001010901016 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001010904942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001011001016 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001011004942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001011101016 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001011104942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001011201016 | NHSA |
| Hunan Jiudian Pharmaceutical Co., Ltd | 国药准字H20203538 | See source | Category B | XM01AEL283A001011204942 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001011301016 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001011401016 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001011501016 | NHSA |
| Shanghai Xu Dong Hai Pu Pharma Co., Ltd. romanized | 国药准字H20030614 | See source | Category B | XM01AEL283A001020100808 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001020101016 | NHSA |
| Wei Cai (Liaoning) Pharmaceutical Co., Ltd. romanized | 国药准字H20041923 | 60mg | Category B | XM01AEL283A001020101337 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001020201016 | NHSA |
| Chongqing Ke Rui Pharmaceutical (Group) Co., Ltd. romanized | 国药准字H20052275 | See source | Category B | XM01AEL283A001020301016 | NHSA |
| Shanghai Xu Dong Hai Pu Pharma Co., Ltd. romanized | 国药准字H20030614 | See source | Category B | XM01AEL283A001030100808 | NHSA |
| Fujian Dong Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20041143 | See source | Category B | XM01AEL283A017010104876 | NHSA |
| Fujian Dong Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20041143 | See source | Category B | XM01AEL283A017010204876 | NHSA |
| Fujian Dong Rui Pharmaceutical Co., Ltd. romanized | 国药准字H20041143 | See source | Category B | XM01AEL283A017010304876 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 3 filings and 3 distinct first applicants.
Generic 3
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Jiangsu Peng Yao Pharma Co., Ltd. romanized | CYHS2600787 | Generic | 2026/04/08 | Not stated by source | CDE |
| Shanxi Tong Da Pharma Co., Ltd. romanized | CYHS2600508 | Generic | 2026/02/25 | Not stated by source | CDE |
| Da Tong Pharmaceutical (Zhongguo) Co., Ltd. romanized | CYHS2504009 | Generic | 2025/11/19 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 2 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| Jiangsu Peng Yao Pharma Co., Ltd. romanized | CYHS2600787 | Generic | 2026/04/08 | Not stated by source | CDE |
| Shanxi Tong Da Pharma Co., Ltd. romanized | CYHS2600508 | Generic | 2026/02/25 | Not stated by source | CDE |
API registrations
Non-component matches: 21 companies with A status and 6 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 洛索洛芬钠 · No verified English name | Hubei Xun Da Pharma Co., Ltd. romanized | Y20260000755 | I | Exact ingredient | 2026/10/29 | CDE |
| 洛索洛芬钠 · No verified English name | Zhejiang Shang Tai Biopharmaceutical Co., Ltd. romanized | Y20260000660 | I | Exact ingredient | 2026/08/28 | CDE |
| 洛索洛芬钠 · No verified English name | Wu Di Rong Chuan Pharmaceuticals Chemical Technology Co., Ltd. romanized | Y20260000514 | I | Exact ingredient | 2026/08/13 | CDE |
| 洛索洛芬钠 · No verified English name | Yi Chang Dong Yang Guang Pharmaceutical Co., Ltd. romanized | Y20250001458 | I | Exact ingredient | 2026/01/30 | CDE |
| 洛索洛芬钠 · No verified English name | DONGBANG FUTURE TECH & LIFE CO., LTD. | Y20240000410 | I | Exact ingredient | 2025/10/10 | CDE |
| 洛索洛芬钠 · No verified English name | Henan Hua Shang Pharma Co., Ltd. romanized | Y20250000238 | A | Exact ingredient | 2026/08/31 | CDE |
| 洛索洛芬钠 · No verified English name | KOLON LIFE SCIENCE, INC. | Y20240001168 | I | Exact ingredient | 2025/02/21 | CDE |
| 洛索洛芬钠 · No verified English name | Anhui Ding Wang Pharmaceuticals Co., Ltd. romanized | Y20240001477 | A | Exact ingredient | 2026/06/01 | CDE |
| 洛索洛芬钠 · No verified English name | Ke Luo Yi Pharmaceutical Co., Ltd. romanized | Y20240001406 | A | Exact ingredient | 2026/05/07 | CDE |
| 洛索洛芬钠 · No verified English name | Metrochem API Private Limited | Y20240000043 | A | Exact ingredient | 2026/04/21 | CDE |
| 洛索洛芬钠 · No verified English name | Zhejiang Pu Luo Jia Yuan Pharma Co., Ltd. romanized | Y20220000630 | A | Exact ingredient | 2026/10/10 | CDE |
| 洛索洛芬钠 · No verified English name | Jin Hong Pharma Co., Ltd. romanized | Y20220000512 | A | Exact ingredient | 2024/11/01 | CDE |
| 洛索洛芬钠 · No verified English name | Zhejiang Si Tai Li Pharmaceutical Co., Ltd. romanized | Y20220000226 | A | Exact ingredient | 2024/02/02 | CDE |
| 洛索洛芬钠 · No verified English name | Hunan Jiu Dian Hong Yang Pharmaceutical Co., Ltd. romanized | Y20210001086 | A | Exact ingredient | 2025/06/28 | CDE |
| 洛索洛芬钠 · No verified English name | Anlon Healthcare Limited | Y20210000754 | A | Exact ingredient | 2026/08/30 | CDE |
| 洛索洛芬钠 · No verified English name | Daito Pharmaceutical Co., Ltd. | Y20190021419 | A | Exact ingredient | 2026/07/17 | CDE |
| 洛索洛芬钠 · No verified English name | SHIN POONG Pharmaceutical Co.,Ltd. | Y20190009153 | A | Exact ingredient | — | CDE |
| 洛索洛芬钠 · No verified English name | DAIICHI SANKYO CO.,LTD. | Y20190009069 | A | Exact ingredient | — | CDE |
| 洛索洛芬钠 · No verified English name | Jilin Ying Lian Biopharmaceutical Co., Ltd. romanized | Y20190008486 | A | Exact ingredient | — | CDE |
| 洛索洛芬钠 · No verified English name | Guo Yao Group Zhi Jun (Suzhou) Pharmaceutical Co., Ltd. romanized | Y20190007938 | A | Exact ingredient | — | CDE |
| 洛索洛芬钠 · No verified English name | Fujian Hui Tian Bio Pharma Co., Ltd. romanized | Y20190007830 | A | Exact ingredient | 2024/08/01 | CDE |
| 洛索洛芬钠 · No verified English name | Xing An Pharma Co., Ltd. romanized | Y20190007805 | A | Exact ingredient | — | CDE |
| 洛索洛芬钠 · No verified English name | Shanghai Xin Lian Chemical Pharmaceutical Co., Ltd. romanized | Y20190007713 | A | Exact ingredient | 2025/01/03 | CDE |
| 洛索洛芬钠 · No verified English name | Di Jia Pharma Group Co., Ltd. romanized | Y20190007707 | A | Exact ingredient | 2026/09/29 | CDE |
| 洛索洛芬钠 · No verified English name | Chongqing Xi Nan Pharmaceutical Er Factory Co., Ltd. romanized | Y20170002341 | A | Exact ingredient | 2024/03/14 | CDE |
| 洛索洛芬钠 · No verified English name | Shandong Luo Xin Pharma Group Heng Xin Pharma Co., Ltd. romanized | Y20170002291 | A | Exact ingredient | 2024/10/24 | CDE |
| 洛索洛芬钠 · No verified English name | Di Yi San Gong Zhu Shi Hui She romanized | Y20170001957 | A | Exact ingredient | 2019/04/22 | CDE |
| 洛索洛芬钠 · No verified English name | Shandong Luo Xin Pharma Group Heng Xin Pharma Co., Ltd. romanized | Y20170000454 | A | Exact ingredient | 2023/08/18 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
- No matching records were found in the currently loaded source data; coverage dates are listed below.
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/13 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/13 06:39
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/13 06:41
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/13 08:09 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Loxoprofen Sodium Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy